|

All-trans Retinoic Acid in combination with the KPD Regimen Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • The First Affiliated Hospital of Xiamen University1

Indications

  • Multiple Myeloma, Refractory1
  • Multiple Myeloma in Relapse1
  • Cancer1

Other1 trial

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.